Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14207346 | 0.83 | GRIN1 (0.39) | GRIN2BTSHRGRIN1LMNASMN1; SMN2 | |
| SCHEMBL4060580 | 0.79 | HDAC1 (0.64) | HDAC1HDAC6TSHRLMNACYP11B2 | |
| SCHEMBL4070370 | 0.77 | NAMPT (0.46) | HDAC1HDAC6HDAC8GRIN2BGRIN1 | |
| SCHEMBL8783707 | 0.76 | GRIN2B (0.67) | HDAC1HDAC6HDAC8GRIN2BGRIN1 | |
| SCHEMBL14207345 | 0.76 | GRIN2B (0.51) | HDAC1HDAC6HDAC8GRIN2BTSHR | |
| SCHEMBL14207337 | 0.76 | GRIN2B (0.51) | HDAC1HDAC6HDAC8GRIN2BGRIN1 | |
| SCHEMBL4072412 | 0.75 | CXCR4 (0.47) | — | |
| SCHEMBL4061273 | 0.74 | ITGB1 (0.38) | TSHRPOLBLMNASMN1; SMN2NAMPT | |
| SCHEMBL4071953 | 0.72 | P2RX7 (0.42) | HDAC1HDAC6TSHRPOLBHPGD | |
| SCHEMBL29823333 | 0.71 | GRIN2B (0.49) | HDAC1HDAC6HDAC8GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | claimed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885HDAC8 1707/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885HDAC8 1707/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885HDAC8 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.